BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
See today's BioWorld
Home
» XTL Shares Nearly Wiped Out After Failed Nerve Pain Study
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
XTL Shares Nearly Wiped Out After Failed Nerve Pain Study
Nov. 19, 2008
By
Catherine Hollingsworth
No Comments
XTL Biopharmaceuticals Ltd. said that a Phase II study of its bicifadine for the treatment of diabetic nerve pain did not meet any of its objectives, causing the company's shares to fall 94.4 percent. (BioWorld Today)
BioWorld